S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Abacus Health Products Stock Forecast, Price & News

-0.26 (-5.10 %)
(As of 06/11/2020)
Today's Range
Now: $4.84
50-Day Range
MA: $4.84
52-Week Range
Now: $4.84
Volume9,300 shs
Average Volume10,164 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.


Overall MarketRank

0.44 out of 5 stars

Medical Sector

1642nd out of 1,926 stocks

Drug Manufacturers - Specialty & Generic Industry

58th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.26 (-5.10 %)
(As of 06/11/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive ABAHF News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAHF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Abacus Health Products (OTCMKTS:ABAHF) Frequently Asked Questions

How has Abacus Health Products' stock been impacted by COVID-19 (Coronavirus)?

Abacus Health Products' stock was trading at $2.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABAHF shares have increased by 68.1% and is now trading at $4.84.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Abacus Health Products?

Wall Street analysts have given Abacus Health Products a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abacus Health Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Abacus Health Products' key competitors?

What is Abacus Health Products' stock symbol?

Abacus Health Products trades on the OTCMKTS under the ticker symbol "ABAHF."

How do I buy shares of Abacus Health Products?

Shares of ABAHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abacus Health Products' stock price today?

One share of ABAHF stock can currently be purchased for approximately $4.84.

What is Abacus Health Products' official website?

The official website for Abacus Health Products is abacushp.com.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.